Article PDF
Avoid common mistakes on your manuscript.
References
Laniosz V, Lehman JS, Poland GA, Wetter DA. Literature-based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses. Int J Dermatol 2016; 55: 599–607.
Polack FP, Thomas SJ, Kitchin N, et al, & C4591001 Clinical trial group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383: 2603–15.
Baden LR, El Sahly HM, Essink B, et al, & COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020; 30: NEJMoa2035389.
Voysey M, Clemens SAC, Madhi SA, et al, & Oxford COVID vaccine trial group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111.
Centers for disease control and prevention. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States.https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.(accessed 28 Jan 2021).
Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79: 39–52.
Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol 2020; 82: e235–6.
Rubin LG, Levin MJ, Ljungman P, et al. Infectious diseases society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: 309–18.
Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology 2020; 95: e1999–2008.
Nagel A, Podstawa E, Eickmann M, et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009; 129: 2202–10.
Neri I, Greco A, Bassi A, et al. Bullous pemphigoid in infant post vaccination: myth or reality? Int J Immunopathol Pharmacol 2016; 29: 295–9.
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020; 586: 594–9.
Moro F, Fania L, Sinagra JLM, Salemme A, Zenzo GD. Bullous pemphigoid: trigger and predisposing factors. Biomolecules 2020; 10: 1432.
Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev 2011; 10: 527–35.
Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun 2020; 3: 100051.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure
Conflicts of interest: none
About this article
Cite this article
Cozzani, E., Gasparini, G., Sticchi, L. et al. Considerations on SARS-CoV-2 vaccines in patients with autoimmune blistering diseases. Eur J Dermatol 31, 415–417 (2021). https://doi.org/10.1684/ejd.2021.4043
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2021.4043